Sunshine Biopharma Inc. (NASDAQ: SBFM) announced the closing of its previously disclosed public offering, raising approximately $6 million in gross proceeds before deducting fees and expenses. The offering involved the sale of 12 million common units, each consisting of one share of common stock (or a pre-funded warrant in lieu thereof) and two Series C warrants. Aegis Capital Corp. served as the exclusive placement agent for the transaction.
The company stated that net proceeds from the offering will be used for general corporate purposes and working capital. Additionally, if the Series C warrants are fully exercised for cash, Sunshine Biopharma could receive up to approximately $12 million in additional gross proceeds. This capital infusion comes at a critical time as the company balances its commercial operations with research and development initiatives.
Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with plans to launch 12 additional products during the remainder of 2026. The company’s generic portfolio provides a steady revenue stream that supports its proprietary drug development programs. These include K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer, and a PLpro protease inhibitor, a small-molecule antiviral candidate designed to treat SARS-related coronavirus infections.
The successful completion of the offering strengthens Sunshine Biopharma’s balance sheet and provides flexibility to execute its business strategy. For leaders in the pharmaceutical and biotech sectors, this move signals the company’s commitment to expanding its generic drug footprint while simultaneously advancing high-risk, high-reward R&D projects. The potential $12 million from warrant exercises could further accelerate these programs, though warrant exercise depends on market conditions and investor decisions.
The offering also highlights the ongoing appetite for investment in companies bridging generic pharmaceuticals and innovative therapeutics. With the Canadian generic market as a foundation, Sunshine Biopharma is positioning itself to compete in both the established generics space and emerging fields like mRNA-based cancer treatments. The company’s progress in these areas could have implications for the broader healthcare industry, particularly in oncology and antiviral therapies.
Full details of the offering are available in the press release at https://ibn.fm/XuHPC. Additional information about Sunshine Biopharma’s operations and pipeline can be found on its website at https://sunshinebiopharma.com/.
